The multifaceted therapeutic potential of benfotiamine

Pharmacological Research

Volumn 61, Issue 6, 2010, Pages 482-488

  Balakumar, Pitchai ^a   Rohilla, Ankur ^b   Krishan, Pawan ^c   Solairaj, Ponnu ^a   Thangathirupathi, Arunachalam ^a  

^a SB College of Pharmacy   (India)

^b MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

^c PUNJABI UNIVERSITY   (India)

Author keywords

AGEs; Benfotiamine; Cardiomyopathy; Endothelial dysfunction; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; BENFOTIAMINE; CYANOCOBALAMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CDC42; THIAMINE; TRANSKETOLASE;

ALCOHOLISM; BLOOD VESSEL TONE; CARDIOMYOPATHY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; ENDOTHELIUM CELL; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HYDROLYSIS; KIDNEY FUNCTION; MONOCYTE; NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; UPREGULATION;

ANIMALS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; THIAMINE;

EID: 77952798449     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.02.008     Document Type: Review

References (72)

1. Thornalley P.J. The potential role of thiamine (vitamin B(1)) in diabetic complications. Curr Diab Rev 2005, 1:287-298.
2. Malecka S.A., Poprawski K., Bilski B. Prophylactic and therapeutic application of thiamine (vitamin B1)-a new point of view. Wiad Lek 2006, 59:383-387.
3. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
4. Wu S., Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett 2006, 394:158-162.
5. Stracke H., Hammes H.P., Werkmann D., Mavrakis K., Bitsch I., Netzel M., et al. Efficacy of benfotiamine versus thiamin on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diab 2001, 109:330-336.
6. Stirban A., Negrean M., Stratmann B., Gotting C., Salomon J., Kleesiek K., et al. Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method. Diabetes Care 2007, 30:2514-2516.
7. Lin J., Alt A., Liersch J., Bretzel R.G., Brownlee M.A., Hammes H.P. Benfotiamine inhibits intracellular formation of advanced glycation endproducts in vivo. Diabetes 2000, 49:P583.
8. Babaei-Jadidi R., Karachalias N., Ahmed N., Battah S., Thornalley P.J. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003, 52:2110-2120.
9. Stirban A., Negrean M., Stratmann B., Gawlowski T., Horstmann T., Gotting C., et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006, 29:2064-2071.
10. Volvert M.L., Seyen S., Piette M., Evrard B., Gangolf M., Plumier J.C., et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol 2008, 8:10.
11. Ceylan-Isik A.F., Wu S., Li Q., Li S.Y., Ren J. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol 2006, 100:150-156.
12. Woelk H., Lehrl S., Bitsch R., Kopcke W. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I study). Alc Alc 1998, 33:631-638.
13. Winkler G., Pal B., Nagybeganyi E., Ory I., Porochnavec M., Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999, 49:220-224.
14. Haupt E., Ledermann H., Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005, 43:71-77.
15. Gadau S., Emanueli C., Van Linthout S., Graiani G., Todaro M., Meloni M., et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006, 49:405-420.
16. Pomero F., Molinar Min A., La Selva M., Allione A., Molinatti G.M., Porta M. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 2001, 38:135-138.
17. Beltramo E., Berrone E., Buttiglieri S., Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diab Metab Res Rev 2004, 20:330-336.
18. Balakumar P., Sharma R., Singh M. Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol Res 2008, 58:356-363.
19. Balakumar P., Chakkarwar V.A., Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009, 320:149-162.
20. Fujiwara M., Watanabe H., Matsui K. Allithiamine, a newly found derivative of vitamin B1. J Biochem 1954, 41:29-39.
21. Bitsch R., Wolf M., Moller J., Heuzeroth L., Gruneklee D. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamine derivative. Ann Nutr Metab 1991, 35:292-296.
22. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 1996, 34:47-50.
23. Yadav U.C.S., Subramanyam S., Ramana K.V. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamine B1. Invest Ophthalmol Vis Sci 2009, 50:2276-2282.
24. Shindo H., Okamoto K., Tohtsu J., Takahashi I. Studies on the absorption of S-benzoylthiamine O-monophosphate. II. Permeability to red cell membranes. Vitamins 1968, 38:21-29.
25. Shindo H., Okamoto K., Wada T., Koike H., Kumakura S. Studies on the absorption of S-benzoylthiamine O-monophosphate. III. Mechanism of the intestinal absorption. Vitamins 1968, 38:30-37.
26. Greb A., Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther 1998, 36:216-221.
27. Loew D. Development and pharmacokinetics of benfotiamine. Benfotiamine in the Therapy of Polyneuropathy 1998, 19-27. Georg Thieme Verlag, New York. F.A. Gries, K. Federlin (Eds.).
28. Gleiter C.H., Schreeb K.H., Freudenthaler S. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamin mononitrate. Benfotiamine in the Therapy of Polyneuropathy 1998, 29-33. Georg Thieme Verlag, New York. F.A. Gries, K. Federlin (Eds.).
29. Hilbig R., Rahmann H. Comparative autoradiographic investigations on the tissue distribution of Benfotiamine versus thiamin in mice. Arzneimittelforschung 1998, 48:461-468.
30. Hatfield J. Advanced glycation end-products (AGEs) in hyperglycemic patients. J Young Invest 2005, 13:1.
31. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
32. Chellan P., Nagaraj R.H. Early glycation products produce pentosidine cross-links on native proteins. J Biol Chem 2001, 276:3895-3903.
33. Wautier J.L., Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004, 95:233-238.
34. Booth A.A., Khalifah R.G., Hudson B.G. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996, 220:113-119.
35. Goh S.Y., Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008, 93:1143-1152.
36. Huijberts M.S.P., Schaper N.C., Schalkwijk C.G. Advanced glycation end products and diabetic foot disease. Diab Metab Res Rev 2008, 24:S19-S24.
37. Lin R.Y., Choudhury R.P., Cai W., Lu M., Fallon J.T., Fisher E.A., et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003, 168:213-220.
38. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
39. Chen A.S., Taguchi T., Sugiura M., Wakasugi Y., Kamei A., Wang M.W., et al. Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm Metab Res 2004, 36:183-187.
40. Wada R., Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann NY Acad Sci 2005, 1043:598-604.
41. Shimoike T., Inoguchi T., Umeda F., Nawata H., Kawano K., Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000, 49:1030-1035.
42. Sebekova K., Faist V., Hofmann T., Schinzel R., Heidland A. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am J Kidney Dis 2003, 41:S48-S51.
43. Boehm B.O., Schilling S., Rosinger S., Lang G.E., Lang G.K., Kientsch-Engel R., et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004, 47:1376-1379.
44. Fosmark D.S., Torjesen P.A., Kilhovd B.K., Berg T.J., Sandvik L., Hanssen K.F., et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 2006, 55:232-236.
45. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran L.J., et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001, 21:905.
46. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280:685-694.
47. Li S.Y., Sigmon V.K., Babcock S.A., Ren J. Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci 2007, 80:1051-1056.
48. Stracke H., Lindemann A., Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diab 1996, 104:311-316.
49. Cameron N.E., Gibson T.M., Nangle M.R., Cotter M.A. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann NY Acad Sci 2005, 1043:784-792.
50. Simeonov S., Pavlova M., Mitkov M., Mincheva L., Troev D. Therapeutic efficacy of " Milgamma" in patients with painful diabetic neuropathy. Folia Med 1997, 39:5-10.
51. Kathleen A., Head N.D. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Alt Med Rev 2006, 11:4.
52. Sanchez-Ramirez G.M., Caram-Salas N.L., Rocha-GonzAlez H.I., Vidal-Cantu G.C., Medina-Santillan R., Reyes-García G., et al. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol 2006, 530:48-53.
53. Beltramo E., Berrone E., Tarallo S., Porta M. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol 2008, 45:131-141.
54. Varkonyi T., Kempler P. Diabetic neuropathy: new strategies for treatment. Diab Obes Metab 2008, 10:99-108.
55. Balakumar P., Arora M.K., Ganti S.S., Reddy J., Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 2009, 60:24-32.
56. Balakumar P., Chakkarwar V.A., Krishan P., Singh M. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?. Biomed Pharmacother 2009, 63:171-179.
57. Balakumar P., Arora M.K., Reddy J., Anand-Srivastava M.B. Pathogenesis of diabetic nephropathy: involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol 2009, 54:129-138.
58. Bakker S.J., Heine R.J., Gans R.O. Thiamine may indirectly act as an antioxidant. Diabetologia 1997, 40:741-742.
59. Thornalley P.J., Babaei-Jadidi R., Al Ali H., Rabbani N., Antonysunil A., Larkin J., et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007, 50:2164-2170.
60. Karachalias N., Babaei-Jadidi R., Ahmed N., Thornalley P.J. Accumulation of fructosyllysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003, 6:1423-1425.
61. Chang L.K., Sarraf D. Current and future approaches in the prevention and treatment of diabetic retinopathy. Clin Ophthalmol 2008, 2:425-433.
62. Bergfeld R., Matsumara T., Du X., Brownlee M. Benfotiamin prevents the consequences of hyperglycemia induced mitochondrial overproduction of reactive oxygen species and experimental diabetic retinopathy. Diabetologia 2001, 44:A39.
63. Obrenovich M.E., Monnier V.M. Vitamin B1 blocks damage caused by hyperglycemia. Sci Aging Knowledge Environ 2003, 2003:6.
64. Chung S.S.M., Ho E.C.M., Lam K.S.L., Chung S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003, 14:S233-S236.
65. Berrone E., Beltramo E., Solimine C., Ape A.U., Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006, 281:9307-9313.
66. Beltramo E., Berrone E., Tarallo S., Porta M. Different apoptotic responses of human and bovine pericytes to fluctuating glucose levels and protective role of thiamine. Diab Metab Res Rev 2009, 25:566-576.
67. Tarallo S., Beltramo E., Berrone E., Dentelli P., Porta M. Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetol 2009, 10.1007/s00592-009-0124-5.
68. Balakumar P., Kaur T., Singh M. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology 2008, 245:49-64.
69. Verma S., Reddy K., Balakumar P. The defensive effect of benfotiamine in sodium arsenite-induced experimental vascular endothelial dysfunction. Biol Trace Elem Res 2009, 10.1007/s12011-009-8567-7.
70. Ma H., Li S.Y., Xu P., Babcock S.A., Dolence E.K., Brownlee M., et al. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) upregulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 2009, 13:1751-1764.
71. Ang C.D., Alviar M.J., Dans A.L., Bautista-Velez G.G., Villaruz-Sulit M.V., Tan J.J., et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev 2008, 3. CD004573.
72. Head K.A. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006, 11:294-329.